Movement Alert｜Akeso Bio Rises 3.13% in Regular Trading, Board Approves HK$200 Million Buyback Plan and Management Pledges HK$50 Million in Open-Market Purchases

Market Focus06-12

On June 12, Akeso Bio rose 3.13% in regular trading, trading at HK$89.35/share, with turnover of HK$356 million. The rebound follows a significant corporate action announced the prior day.

On June 11, Akeso Bio disclosed that its board approved a plan to deploy up to HK$200 million to purchase company shares on the open market, executed through the trustee of its 2021 restricted share unit scheme and funded by existing cash resources. Concurrently, Chairwoman and CEO Dr. Xia Yu, along with executive directors Dr. Li Baiyong, Dr. Wang Zhongmin, Dr. Zhang Peng, and CFO Dr. Wang Bingzhong, announced intentions to collectively acquire up to HK$50 million in shares using personal funds. The board stated that the current trading price does not reflect the company's intrinsic value and business prospects.

The stock had declined over 30% from its June 1 post-ASCO high, approaching 52-week lows, before the buyback announcement provided a near-term floor.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167015341?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167015341","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Bio Rises 3.13% in Regular Trading, Board Approves HK$200 Million Buyback Plan and Management Pledges HK$50 Million in Open-Market Purchases","media":"Market Focus","content":"<p><p>On June 12, Akeso Bio rose 3.13% in regular trading, trading at HK$89.35/share, with turnover of HK$356 million. The rebound follows a significant corporate action announced the prior day.</p><p>On June 11, Akeso Bio disclosed that its board approved a plan to deploy up to HK$200 million to purchase company shares on the open market, executed through the trustee of its 2021 restricted share unit scheme and funded by existing cash resources. Concurrently, Chairwoman and CEO Dr. Xia Yu, along with executive directors Dr. Li Baiyong, Dr. Wang Zhongmin, Dr. Zhang Peng, and CFO Dr. Wang Bingzhong, announced intentions to collectively acquire up to HK$50 million in shares using personal funds. The board stated that the current trading price does not reflect the company's intrinsic value and business prospects.</p><p>The stock had declined over 30% from its June 1 post-ASCO high, approaching 52-week lows, before the buyback announcement provided a near-term floor.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Bio Rises 3.13% in Regular Trading, Board Approves HK$200 Million Buyback Plan and Management Pledges HK$50 Million in Open-Market Purchases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Bio Rises 3.13% in Regular Trading, Board Approves HK$200 Million Buyback Plan and Management Pledges HK$50 Million in Open-Market Purchases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, Akeso Bio rose 3.13% in regular trading, trading at HK$89.35/share, with turnover of HK$356 million. The rebound follows a significant corporate action announced the prior day.</p><p>On June 11, Akeso Bio disclosed that its board approved a plan to deploy up to HK$200 million to purchase company shares on the open market, executed through the trustee of its 2021 restricted share unit scheme and funded by existing cash resources. Concurrently, Chairwoman and CEO Dr. Xia Yu, along with executive directors Dr. Li Baiyong, Dr. Wang Zhongmin, Dr. Zhang Peng, and CFO Dr. Wang Bingzhong, announced intentions to collectively acquire up to HK$50 million in shares using personal funds. The board stated that the current trading price does not reflect the company's intrinsic value and business prospects.</p><p>The stock had declined over 30% from its June 1 post-ASCO high, approaching 52-week lows, before the buyback announcement provided a near-term floor.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1167015341","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167015341","pubTimestamp":1781230203,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, Akeso Bio rose 3.13% in regular trading, trading at HK$89.35/share, with turnover of HK$356 million. The rebound follows a significant corporate action announced the prior day.On June 11,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动静|康方生物常规交易涨3.13%董事会批准2亿港元回购计划管理层承诺5000万港元公开市场购买","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 12, Akeso Bio rose 3.13% in regular trading, trading at HK$89.35/share, with turnover of HK$356 million. The rebound follows a significant corporate action announced the prior day.On June 11, Akeso Bio disclosed that its board approved a plan to deploy up to HK$200 million to purchase company shares on the open market, executed through the trustee of its 2021 restricted share unit scheme and funded by existing cash resources. Concurrently, Chairwoman and CEO Dr. Xia Yu, along with executive directors Dr. Li Baiyong, Dr. Wang Zhongmin, Dr. Zhang Peng, and CFO Dr. Wang Bingzhong, announced intentions to collectively acquire up to HK$50 million in shares using personal funds. The board stated that the current trading price does not reflect the company's intrinsic value and business prospects.The stock had declined over 30% from its June 1 post-ASCO high, approaching 52-week lows, before the buyback announcement provided a near-term floor.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167015341","isCrawlerRequest":true}